PMID- 24682499
OWN - NLM
STAT- MEDLINE
DCOM- 20150303
LR  - 20211021
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 231
IP  - 15
DP  - 2014 Aug
TI  - The effects of lobeline on nicotine withdrawal-induced depression-like behavior 
      in mice.
PG  - 2989-98
LID - 10.1007/s00213-014-3472-y [doi]
AB  - RATIONALE: Evidence suggests that neuronal nicotinic acetylcholine receptor 
      (nAChR) ligand lobeline has antidepressant-like properties. OBJECTIVES: The 
      present study investigated the effects of lobeline on nicotine withdrawal-induced 
      depression-like behavior. METHODS: Adult C57BL/6J mice were exposed to nicotine 
      (200 mug/ml) in drinking solution for 3 weeks. During withdrawal, depression-like 
      behavior was measured by the forced swim test (FST). We also determined 
      norepinephrine (NE) levels in the prefrontal cortex (PFC) and hippocampus during 
      nicotine withdrawal. Furthermore, we determined the effects of repeated treatment 
      with lobeline or a selective alpha4beta2 nAChR ligand 3-(pyridine-3́-yl)-cytisine on 
      brain-derived neurotrophic factor (BDNF) and phosphorylated cAMP-responsive 
      element binding (p-CREB) protein expression in the hippocampus. RESULTS: 
      Withdrawal from chronic nicotine increased immobility time in the FST, a measure 
      for depression-like behavior. Pretreatment with lobeline significantly decreased 
      immobility time during nicotine withdrawal. In addition, pretreatment with 
      lobeline attenuated nicotine withdrawal-induced increased NE levels in the PFC 
      and hippocampus. Further, repeated treatment with lobeline or 
      3-(pyridine-3́-yl)-cytisine decreased immobility time in the FST and reduced 
      withdrawal-induced increased BDNF and p-CREB expression in the hippocampus. 
      CONCLUSIONS: Taken together, our results indicate that lobeline attenuated 
      nicotine withdrawal-induced depression-like behavior likely by targeting brain 
      nAChRs, noradrenergic neurotransmission, and/or hippocampal BDNF. Thus, lobeline 
      may have some potential to prevent smoking relapse by counteracting nicotine 
      withdrawal-induced depression in humans.
FAU - Roni, Monzurul Amin
AU  - Roni MA
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State 
      University, Avera Health and Science Center, SAV 265, Brookings, SD, 57007, USA.
FAU - Rahman, Shafiqur
AU  - Rahman S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140228
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Creb1 protein, mouse)
RN  - 0 (Cyclic AMP Response Element-Binding Protein)
RN  - 0 (Nicotinic Agonists)
RN  - 0 (Receptors, Nicotinic)
RN  - 0 (nicotinic receptor alpha4beta2)
RN  - 6M3C89ZY6R (Nicotine)
RN  - D0P25S3P81 (Lobeline)
RN  - K5161X06LL (Cotinine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Cotinine/blood
MH  - Cyclic AMP Response Element-Binding Protein/metabolism
MH  - Depression/*drug therapy/physiopathology
MH  - Disease Models, Animal
MH  - Hippocampus/drug effects/physiopathology
MH  - Lobeline/*pharmacology
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Motor Activity/drug effects/physiology
MH  - Neuropsychological Tests
MH  - Nicotine/*pharmacology
MH  - Nicotinic Agonists/*pharmacology
MH  - Norepinephrine/metabolism
MH  - Prefrontal Cortex/drug effects/physiopathology
MH  - Receptors, Nicotinic/metabolism
MH  - Substance Withdrawal Syndrome/*drug therapy/physiopathology
MH  - Swimming
MH  - Tobacco Use Disorder/physiopathology
EDAT- 2014/04/01 06:00
MHDA- 2015/03/04 06:00
CRDT- 2014/04/01 06:00
PHST- 2013/09/04 00:00 [received]
PHST- 2014/01/27 00:00 [accepted]
PHST- 2014/04/01 06:00 [entrez]
PHST- 2014/04/01 06:00 [pubmed]
PHST- 2015/03/04 06:00 [medline]
AID - 10.1007/s00213-014-3472-y [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2014 Aug;231(15):2989-98. doi: 
      10.1007/s00213-014-3472-y. Epub 2014 Feb 28.